



Beijing Savant Biotechnology Co., Ltd.

Company Profile


Company Profile


Beijing Savant Biotechnology Co., Ltd.

- **Savant** was founded in 2007 , which is a high-tech enterprise focusing on quantitative immunoassay.
- With the business principle of "Leading the innovation of technology, developing stable and consistent products", specializing in the research, production and sales of In Vitro diagnostic reagents and instruments.
- At present, it has two major product lines of chemiluminescence and POCT, with 108 items of industrial products, which have been widely used in domestic medical institutions at all levels.
- There are more than 350 employees, of which 20% are R&D personnel, 35% have bachelor's degree or above, and 10% have master's degree or above.
- With strong scientific research strength, we have established extensive and close cooperation with many domestic universities, research institutes and medical institutions, etc., and are committed to the development of IVD cause.





Company structure






Focus on Field of Quantitative Immunoassay | Own Core Technologies

Core technology




Fluorescence Microsphere Dry Quantification Technology




Directional Marking Technology

Guarantee the Integrity of binding sites

Product route



R&Ddirection



**Homogeneous electrochemical
immunoassay platform**




**Online isolation mass spectrometry
immunoassay system**



**Magnetic particle immunoassay
system**

Intellectual Property



Enterprise honor



Key products : Covid-19 Antigen test

国家重点研发计划 项目任务书

项目名称:	新型冠状病毒肺炎抗原检测系统的研发
所属专项:	公共安全风险防控与应急技术装备
指南方向:	2 抗原快速检测试剂
推荐单位:	无
项目管理专业机构:	中国 21 世纪议程管理中心
项目牵头承担单位:	北京华科泰生物技术股份有限公司 (公章)
项目负责人:	林斯
执行期限:	2020 年 02 月 至 2020 年 04 月

中华人民共和国科学技术部制
2020 年 03 月 29 日

国务院应对新型冠状病毒感染的肺炎 疫情联防联控机制(科研攻关组)办公室

关于推荐检测试剂应急项目有关产品进入 应急审批通道的函

3	2. 抗原快速检测试剂	适宜于疫情现场的新型 冠状病毒抗原快速检测 试剂开发	广州万孚生物 技术股份有限 公司	康可人
4		新型冠状病毒肺炎抗原 检测系统的研发	北京华科泰生 物技术股份有 限公司	林斯
5		新型冠状病毒 (2019-nCoV) 抗原检测 试剂盒的研究开发	北京金沃夫生 物工程科技有 限公司	阎锡新

Key products : Covid-19 Antigen test

2020/11/6 Frontiers | Foundation and Clinical Evaluation of a New Method for Detecting SARS-CoV-2 Antigen by Fluorescent Microsphere Imm...

<https://www.frontiersin.org>LOGIN ([HTTPS://WWW.FRONTIERSIN.ORG/PEOPLE/LOGIN](https://www.frontiersin.org/people/login)) / REGISTER ([HTTPS://WWW.FRONTIERSIN.ORG/REGISTER](https://www.frontiersin.org/register)) ABOUT ([HTTPS://WWW.FRONTIERSIN.ORG/ABOUT](https://www.frontiersin.org/about)) ABOUT-FRONTIERSIN ([HTTPS://WWW.FRONTIERSIN.ORG/ABOUT](https://www.frontiersin.org/about))

0 0 0 New

ORIGINAL RESEARCH ARTICLE

Front. Cell. Infect. Microbiol. | doi: 10.3389/fcimb.2020.553837

Foundation and Clinical Evaluation of a New Method for Detecting SARS-CoV-2 Antigen by Fluorescent Microsphere Immunochromatography

Provisionally accepted

The final, formatted version of

the article will be published soon. [Notify me \(\)](#)

[Chunyan Zhang \(https://loop.frontiersin.org/people/957850/overview\)](https://loop.frontiersin.org/people/957850/overview)¹, [Lei Zhou \(https://loop.frontiersin.org/people/1119733/overview\)](#)^{2, 3}, [Kang Du](#)⁴, [Ying Zhang](#)⁵, [Jing Wang](#)⁶, [Lijuan Chen \(https://loop.frontiersin.org/people/617419/overview\)](#)⁷, [Yanning Lyu](#)⁷, [Jun Li](#)⁵, [Hao Liu](#)^{2, 3, 8}, [Junli Huo](#)^{2, 3, 8}, [Fei Li](#)^{2, 3}, [Jiayi Wang](#)^{2, 3, 9}, [Peipei Sang](#)¹⁰, [Si Lin](#)¹¹, [Yi Xiao](#)

Key products : POCT—Maternal and child testing series

Protect women's and children's health and ensure a bright future

25羟基维生素D —— 25-OH-VD

25羟基维生素D3 ——25-OH-VD3

铁蛋白——Fer



Key products : POCT—Bone metabolism series



Protect bone health

25 (OH) D\D3
25羟基维生素D\D3

+

N-MID
人N端中段骨钙素

+

PTH
甲状旁腺激素



Tumor markers series

甲胎蛋白 (AFP)

糖类抗原125 (CA125)

糖类抗原 (CA199)

前列腺特异性抗原 (PSA)

糖类抗原724 (CA724)

神经元特异性烯醇化酶 (NSE)

细胞角蛋白19片段 (CY-211)

癌胚抗原 (CEA)

糖类抗原152 (CA153)

胃蛋白酶原I、II (PGI、PGII)

游离前列腺特异性抗原 (f-PSA)

糖类抗原242 (CA242)


鳞状细胞癌相关抗原 (SCC)

人附睾蛋白4 (HE4)



癌

Business income



Rapid growth of performance

Business income(RMB) : Business income(RMB) :

2016 : 123 million

2018 : 203 million

2017 : 157 million

2019 : 208 million

Product capacity

Industrial products : 108 items



POCT series

The monthly output is 3 million tests

Chemiluminescence series

The annual production capacity is 60 million tests

Enterprise scene - Parks in Beijing1



Beijing SAVANT POCT production area

Enterprise scene - Parks in Beijing1



Beijing SAVANT POCT production area

Enterprise scene - Parks in Beijing2



Beijing SAVANT -- Liandong u Valley Jinqiao Park : Administration Center / R & D Center

Production scenario - Parks in Tianjin



The production base / instrument R & D center is expected to be put into operation in March 2021

Production scenario - Parks in Tianjin




Tianjin SAVANT : Conference office area

Production scenario - Parks in Tianjin



Tianjin SAVANT : VIP reception area

Enterprise scene - Parks in Tianjin



Tianjin SAVANT—R & D laboratory and GMP workshop

Enterprise scene - Parks in Tianjin



Tianjin SAVANT : Construction site

Enterprise scene - Parks in Tianjin



Thank you for reading!